Table 1 Clinical characteristics in the study population

n

49

95

Age (years)

59 ± 9

60 ± 10

Males

28 (57.1)

62 (65.3)

Current smoking

34 (69.4)

51 (53.7)

Hypertension

36 (73.5)

65 (68.4)

Hyperlipidemia

32 (65.3)

58 (61.1)

Duration of diabetes (years)

4.2 (2.0, 5.2)

2.5 (1.2, 4.8)

BMI (kg/m²)

26.4 ± 3.6

25.6 ± 3.5

LVEF (%)

59.5 ± 8.3

62.2 ± 9.2

eGFR (mL/min/1.73 m²)

84.6 ± 28.6

88.0 ± 30.8

SBP (mmHg)

130 ± 13

131 ± 16

DBP (mmHg)

76 ± 8

77 ± 10

TG (mmol/L)

1.93 (1.12, 2.13)

1.72 (0.94, 1.88)

HDL-C (mmol/L)

0.96 (0.82, 1.24)

1.02 (0.91, 1.23)

Non-HDL-C (mmol/L)

4.39 (3.63, 4.99)

3.83 (3.43, 4.36)

WBC (10⁹/L)

7.3 ± 1.6

7.2 ± 1.7

hs-CRP (mg/dL)

2.46 (1.61, 5.23)

1.22 (0.84, 4.01)

NT-proBNP

390 (155, 960)

362 (105, 890)

TnI

1.20 (0.11, 5.12)

0.91 (0.03, 2.62)

Urinary 8-iso-PGF_2α (pmol/mmolCr)

141.9 ± 67.2

116.1 ± 71.6

FBG (mmol/L)

8.1 ± 3.0

7.1 ± 2.0

HbA_1c (%)

7.2 ± 0.5

7.0 ± 0.6

1,5-AG (µg/mL)

10.5 ± 5.5

14.1 ± 7.7

Medications on admission

 Aspirin

36 (73.5)

71 (74.7)

 Statins

27 (55.1)

62 (65.3)

 ACEI/ARB

25 (51.0)

52 (54.7)

 Oral antidiabetic drugs

31 (63.3)

64 (67.4)

 Insulin

16 (32.7)

32 (33.7)